Tag: $Moderna

Shares of Moderna (MRNA) slipped Friday after the drugmaker reported better-than-expected quarterly results.

Moderna (NASDAQ:MRNA) saw its shares rose nearly 5% in premarket trading Monday after the U.S. Food and Drug Administration (FDA) has approved the drugmaker’s next-generation COVID-19 vaccine, mNEXSPIKE, for adults 65 and older, as well as individuals aged 12 to 64 with at least one underlying condition that increases their risk of severe illness.

Moderna on Thursday reported first-quarter profit and sales that beat Wall Street estimates, helped by the company’s cost-cutting efforts following waning post-pandemic demand for its COVID-19 vaccine.

Shares of vaccine maker Moderna dropped more than 5% late Wednesday after reports that the Health and Human Services Department was re-evaluating its $590 million contract to develop a bird flu vaccine.

Moderna reported a bigger-than-expected quarterly loss on Friday, hit by a charge related to its efforts to scale down manufacturing amid weakening demand for its COVID-19 vaccine.

Moderna cut its 2025 sales forecast by $1 billion on Monday, hurt by a slow adoption of its respiratory syncytial virus (RSV) shot and weak demand for COVID-19 vaccines, sending its shares down more than 18% in premarket trading.

Moderna’s third-quarter financial results look far better than analysts anticipated, but the beat seems largely to reflect Americans getting their Covid-19 shots earlier this year than they did last year.

Moderna on Thursday said it plans to cut around $1.1 billion in expenses by 2027 and win approvals for several new products as it charts a path forward after the rapid decline of its Covid business.

Moderna on Thursday reported second-quarter revenue that beat expectations but slashed its full-year sales guidance, citing lower expected sales in Europe, a “competitive environment” for respiratory vaccines in the U.S. and the potential for deferred international revenue into 2025. 

Moderna announced positive clinical trial data on three experimental vaccines and said it will move those shots to final stage studies.

Moderna posted a surprise quarterly profit, in part boosted by deferred revenue, even as the company saw slumping sales from its Covid vaccine, its only marketable product. 

Moderna on Thursday unveiled new data from a continuing early-stage trial of the personalized cancer treatment it is testing with Merck, saying that the updated results help build the case that the drug works.

Moderna posted a loss for the third quarter as demand for its Covid shots declined.

Moderna stock was rising Wednesday after the vaccine maker released positive results from a Phase 3 trial of its mRNA flu vaccine and provided insight on its plans for other vaccines targeting cancer and other diseases

Moderna’s new Covid vaccine generated a strong immune response against BA.2.86, a highly mutated omicron variant that health officials are watching closely, according to clinical trial data the biotech company released Wednesday.

Moderna’s new Covid vaccine generated a robust immune response against the now-dominant Eris variant and another rapidly spreading strain of the virus in an early clinical trial, the biotech company said Thursday. 

Moderna shares were rising early Thursday after the company reported lighter losses and better revenue than expected for the June quarter and raised guidance for sales of its Covid-19 vaccine.